For research use only
| Cat No. | ABC-TC0106 |
| Product Type | Human Kidney Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Renal Cell Cancer |
| Product Code | CAKI-1; CaKi-1; caki-1; CAKI.1; CAKI 1; CAKI1; Caki1 |
Caki-1 cell line provides a human renal carcinoma model for cancer biology research, drug screening, and functional pathway studies in vitro.
Caki-1 is a human clear cell renal cell carcinoma (ccRCC) cell line established in 1971 from a cutaneous metastasis of a 49-year-old Caucasian male patient. These adherent epithelial cells exhibit classic cuboidal morphology, and when cultured on Transwell filters, they form polarized monolayers with apical microvilli and functional tight junctions—features reminiscent of proximal tubule epithelium. Cytogenetically, Caki-1 displays a pseudotetraploid karyotype with chromosomal gains commonly observed in metastatic ccRCC. Genetically, it harbors wild-type VHL but overexpresses VEGF, particularly under hypoxic conditions. Additionally, this line is highly permissive to viral infection and transfection, facilitating mechanistic studies in cancer biology. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | CAKI-1; CaKi-1; caki-1; CAKI.1; CAKI 1; CAKI1; Caki1 |
| Species | Human |
| Cat.No | ABC-TC0106 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Renal Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Kidney Cancer Cell Lines |
Caki-1 serves as a robust in vitro model for investigating metastatic ccRCC. It is especially valuable for exploring tumor angiogenesis, VHL/HIF signaling, and hypoxia-driven VEGF expression. The polarized monolayer architecture makes it ideal for studies of epithelial transport, tight junction integrity, and drug permeability. Moreover, its metastatic origin and tumorigenicity in immunodeficient mice support its use in evaluating metastasis mechanisms, stem-like subpopulations (e.g., CD105⁺ cells), and therapeutic response profiling.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
